We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Kymera Therapeutics Inc (KYMR) USD0.0001

Sell:$40.15 Buy:$43.00 Change: $1.20 (2.94%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$40.15
Buy:$43.00
Change: $1.20 (2.94%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$40.15
Buy:$43.00
Change: $1.20 (2.94%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

Contact details

Address:
500 North Beacon Street, 4Th Floor
WATERTOWN
02472
United States
Telephone:
+1 (857) 2855314
Website:
https://www.kymeratx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KYMR
ISIN:
US5015751044
Market cap:
$2.64 billion
Shares in issue:
64.77 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Nello Mainolfi
    President, Chief Executive Officer, Co-Founder, Director
  • Bruce Jacobs
    Chief Financial Officer
  • Jeremy Chadwick
    Chief Operating Officer
  • Jared Gollob
    Chief Medical Officer
  • Ellen Chiniara
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.